Zydus Lifesciences Limited (NSE:ZYDUSLIFE)
906.65
-3.80 (-0.42%)
At close: Feb 17, 2026
Zydus Lifesciences Revenue
Zydus Lifesciences had revenue of 68.65B INR in the quarter ending December 31, 2025, with 30.28% growth. This brings the company's revenue in the last twelve months to 260.89B, up 17.27% year-over-year. In the fiscal year ending March 31, 2025, Zydus Lifesciences had annual revenue of 232.42B with 18.90% growth.
Revenue (ttm)
260.89B
Revenue Growth
+17.27%
P/S Ratio
3.50
Revenue / Employee
9.35M
Employees
27,917
Market Cap
912.30B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2025 | 232.42B | 36.94B | 18.90% |
| Mar 31, 2024 | 195.47B | 23.10B | 13.40% |
| Mar 31, 2023 | 172.37B | 21.28B | 14.08% |
| Mar 31, 2022 | 151.10B | 7.06B | 4.90% |
| Mar 31, 2021 | 144.04B | 1.50B | 1.06% |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Aurobindo Pharma | 331.82B |
| Cipla | 279.67B |
| Glenmark Pharmaceuticals | 165.10B |
| Alkem Laboratories | 142.53B |
| Mankind Pharma | 139.14B |
| Divi's Laboratories | 103.14B |
| Ipca Laboratories | 95.06B |
| Emcure Pharmaceuticals | 88.50B |
Zydus Lifesciences News
- 21 hours ago - Zydus Lifesciences launches India’s first affordable OPEP device PEPAIR - Business Upturn
- 5 days ago - Zydus Lifesciences Ltd (BOM:532321) Q3 2026 Earnings Call Highlights: Strong Revenue Growth ... - GuruFocus
- 5 days ago - Q3 2026 Zydus Lifesciences Ltd Earnings Call Transcript - GuruFocus
- 5 days ago - Zydus Lifesciences settles US Patent Litigation with Astellas Pharma over Myrbetriq, to pay USD 120 million - Business Upturn
- 8 days ago - Zydus Life shares jump over 4% as Q3 Revenue surge 30.3% YoY to Rs 6,864.5 crore, net profit rises 1.8% - Business Upturn
- 8 days ago - Zydus Lifesciences Q3 Results: Revenue jumps 30.3% YoY to Rs 6,864.5 crore, net profit up 1.8% - Business Upturn
- 8 days ago - Top Q3 results today, Feb 9: BSE, Zydus Lifesciences, Aurobindo Pharma, Pfizer and more to announce earnings - Business Upturn
- 13 days ago - Zydus Lifesciences receives USFDA tentative approval for Dapagliflozin Tablets - Business Upturn